Zscaler Inc vs Zoetis Inc — how do they compare? Zscaler Inc trades at $166.58 (market cap $26.41B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.88% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| ZS | ZTS | |
|---|---|---|
Market Cap | $26.41B | $30.40B |
Sector | Technology | Health |
52-Week High | $336.27 | $150.61 |
52-Week Low | $118.05 | $71.91 |
Enterprise Value | $24.79B | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
Zscaler (ZS) trades at $161.94, down 4.63% amid bearish technical signals despite strong quarterly earnings beats. The stock shows improving fundamentals with revenue growing from $1.1B in 2022 to $2.67B in 2025, though net margins remain negative. Recent news highlights Zscaler's AI security innovations and conference presentations, while analyst consensus remains strongly bullish with a $204.88 price target representing 26% upside potential.
Zscaler presents a compelling growth story with accelerating revenue and strong enterprise adoption, though profitability challenges and elevated valuation metrics warrant caution. The stock's current weakness near support levels offers potential entry points for investors bullish on cybersecurity demand, particularly given Zscaler's leadership in zero-trust security and AI-driven threat protection capabilities.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →